PIK3CB and cancer: The PI3K/AKT/mTOR pathway dysregulation is considered one of the most mutated pathways in cancers and has been found across all human cancers including hematological malignancies, breast, lung, head and neck, glioblastomas, prostate, and gastrointestinal cancers; thus, targeting individual components in this pathway (PI3K, AKT, and mTOR) may be a potential therapeutic treatment for various malignancies [3].